195 related articles for article (PubMed ID: 30223267)
21. Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia.
Burnett AK; Russell NH; Hills RK; Kell J; Freeman S; Kjeldsen L; Hunter AE; Yin J; Craddock CF; Dufva IH; Wheatley K; Milligan D
J Clin Oncol; 2012 Nov; 30(32):3924-31. PubMed ID: 22851554
[TBL] [Abstract][Full Text] [Related]
22. Upfront treatment for newly diagnosed transplant-ineligible multiple myeloma patients: A systematic review and network meta-analysis of 14,533 patients over 29 randomized clinical trials.
Sekine L; Ziegelmann PK; Manica D; Pithan CDF; Sosnoski M; Morais VD; Falcetta FS; Ribeiro MR; Salazar AP; Ribeiro RA
Crit Rev Oncol Hematol; 2019 Nov; 143():102-116. PubMed ID: 31563077
[TBL] [Abstract][Full Text] [Related]
23. Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure.
Wattad M; Weber D; Döhner K; Krauter J; Gaidzik VI; Paschka P; Heuser M; Thol F; Kindler T; Lübbert M; Salih HR; Kündgen A; Horst HA; Brossart P; Götze K; Nachbaur D; Köhne CH; Ringhoffer M; Wulf G; Held G; Salwender H; Benner A; Ganser A; Döhner H; Schlenk RF
Leukemia; 2017 Jun; 31(6):1306-1313. PubMed ID: 28138160
[TBL] [Abstract][Full Text] [Related]
24. The combination of fludarabine, cytarabine and etoposide is an active and well-tolerated regimen in relapsed/refractory acute myeloid leukemia.
Aldoss I; Ji L; Haider M; Pullarkat V
Acta Haematol; 2014; 131(4):202-7. PubMed ID: 24296475
[TBL] [Abstract][Full Text] [Related]
25. [Efficacy of HAA regimen in the treatment of 64 patients with refractory/relapsed acute myeloid leukemia].
Fan C; Yu W; Mai W; Meng H; Qian W; Tong H; Huang J; Mao L; Suo S; Jin J
Zhonghua Xue Ye Xue Za Zhi; 2016 Feb; 37(2):100-4. PubMed ID: 27014977
[TBL] [Abstract][Full Text] [Related]
26. The safety and efficacy of vosaroxin in patients with first relapsed or refractory acute myeloid leukemia - a critical review.
Short NJ; Ravandi F
Expert Rev Hematol; 2016 Jun; 9(6):529-34. PubMed ID: 27158854
[TBL] [Abstract][Full Text] [Related]
27. High dose cytarabine, mitoxantrone and l-asparaginase (HAMA) salvage for relapsed or refractory acute myeloid leukemia (AML) in the elderly.
Ahmed T; Holwerda S; Klepin HD; Isom S; Ellis LR; Lyerly S; Manuel M; Dralle S; Berenzon D; Powell BL; Pardee TS
Leuk Res; 2015 Sep; 39(9):945-9. PubMed ID: 26154683
[TBL] [Abstract][Full Text] [Related]
28. Response Rate, Event-Free Survival, and Overall Survival in Newly Diagnosed Acute Myeloid Leukemia: US Food and Drug Administration Trial-Level and Patient-Level Analyses.
Norsworthy KJ; Gao X; Ko CW; Pulte ED; Zhou J; Gong Y; Shen YL; Vallejo J; Gwise TE; Sridhara R; Deisseroth AB; Farrell AT; de Claro RA; Blumenthal GM; Pazdur R
J Clin Oncol; 2022 Mar; 40(8):847-854. PubMed ID: 34890212
[TBL] [Abstract][Full Text] [Related]
29. Low efficacy and high mortality associated with clofarabine treatment of relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes.
Roberts DA; Wadleigh M; McDonnell AM; DeAngelo DJ; Stone RM; Steensma DP
Leuk Res; 2015 Feb; 39(2):204-10. PubMed ID: 25554239
[TBL] [Abstract][Full Text] [Related]
30. Phase II trial of amsacrine plus intermediate-dose Ara-C (IDAC) with or without etoposide as salvage therapy for refractory or relapsed acute leukemia.
Sung WJ; Kim DH; Sohn SK; Kim JG; Baek JH; Jeon SB; Moon JH; Ahn BM; Lee KB
Jpn J Clin Oncol; 2005 Oct; 35(10):612-6. PubMed ID: 16172175
[TBL] [Abstract][Full Text] [Related]
31. Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group.
Wierzbowska A; Robak T; Pluta A; Wawrzyniak E; Cebula B; Hołowiecki J; Kyrcz-Krzemień S; Grosicki S; Giebel S; Skotnicki AB; Piatkowska-Jakubas B; Kuliczkowski K; Kiełbiński M; Zawilska K; Kłoczko J; Wrzesień-Kuś A;
Eur J Haematol; 2008 Feb; 80(2):115-26. PubMed ID: 18076637
[TBL] [Abstract][Full Text] [Related]
32. Molecular and Pharmacologic Properties of the Anticancer Quinolone Derivative Vosaroxin: A New Therapeutic Agent for Acute Myeloid Leukemia.
Jamieson GC; Fox JA; Poi M; Strickland SA
Drugs; 2016 Sep; 76(13):1245-1255. PubMed ID: 27484675
[TBL] [Abstract][Full Text] [Related]
33. Role of CD19 and specific KIT-D816 on risk stratification refinement in t(8;21) acute myeloid leukemia induced with different cytarabine intensities.
Wang B; Yang B; Ling Y; Zhang J; Hua X; Gu W; Yan F
Cancer Med; 2021 Feb; 10(3):1091-1102. PubMed ID: 33382538
[TBL] [Abstract][Full Text] [Related]
34. Daunorubicin, cytarabine and fludarabine (DAF) for remission induction in relapsed or refractory acute myeloid leukemia. Evaluation of safety, tolerance and early outcome--Polish Adult Leukemia Group (PALG) pilot study.
Hołowiecki J; Grosicki S; Kyrcz-Krzemien S; Skotnicki AB; Piatkowska-Jakubas B; Warzocha K; Seferynska I; Zdziarska B
Ann Hematol; 2008 May; 87(5):361-7. PubMed ID: 18074133
[TBL] [Abstract][Full Text] [Related]
35. Comparison of cladribine- and fludarabine-based induction chemotherapy in relapsed or refractory acute myeloid leukaemia.
Park H; Youk J; Kim I; Yoon SS; Park S; Lee JO; Bang SM; Koh Y
Ann Hematol; 2016 Oct; 95(11):1777-86. PubMed ID: 27539617
[TBL] [Abstract][Full Text] [Related]
36. A Comparison of Clofarabine-based (GCLAC) and Cladribine-based (CLAG) Salvage Chemotherapy for Relapsed/Refractory AML.
Muluneh B; Buhlinger K; Deal AM; Zeidner JF; Foster MC; Jamieson KJ; Bates J; Van Deventer HW
Clin Lymphoma Myeloma Leuk; 2018 Jan; 18(1):e13-e18. PubMed ID: 29100976
[TBL] [Abstract][Full Text] [Related]
37. Impact on acute myeloid leukemia relapse in granulocyte colony-stimulating factor application: a meta-analysis.
Feng X; Lan H; Ruan Y; Li C
Hematology; 2018 Oct; 23(9):581-589. PubMed ID: 29516766
[TBL] [Abstract][Full Text] [Related]
38. Increasing aclarubicin dosage of the conventional CAG (low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor) regimen is more efficacious as a salvage therapy than CAG for relapsed/refractory acute myeloid leukemia.
Qu Q; Liu L; Zhang Y; Li X; Wu D
Leuk Res; 2015 Dec; 39(12):1353-9. PubMed ID: 26432074
[TBL] [Abstract][Full Text] [Related]
39. Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia.
Chevallier P; Delaunay J; Turlure P; Pigneux A; Hunault M; Garand R; Guillaume T; Avet-Loiseau H; Dmytruk N; Girault S; Milpied N; Ifrah N; Mohty M; Harousseau JL
J Clin Oncol; 2008 Nov; 26(32):5192-7. PubMed ID: 18854573
[TBL] [Abstract][Full Text] [Related]
40. Comparison of salvage chemotherapy regimens and prognostic significance of minimal residual disease in relapsed/refractory acute myeloid leukemia.
Mushtaq MU; Harrington AM; Chaudhary SG; Michaelis LC; Carlson KB; Abedin S; Runass L; Callander NS; Fallon MJ; Juckett M; Hall AC; Hematti P; Mattison RJ; Atallah EL; Guru Murthy GS
Leuk Lymphoma; 2021 Jan; 62(1):158-166. PubMed ID: 32951486
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
